Benitec Biopharma Inc. BNTC
9.28 USD +0.88 (+10.48%)
At closeNov 4, 2026, 4:00 PM EST
9.28 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
8.67 Day range 9.39
7.89 52-week range 15.86
- YTD
- -31.11%
- 1 year
- -40.93%
- Market cap
- 323.77M
- EPS (ttm)
- -0.98
- Shares out
- 23.22M
- Forward P/E
- -1.23
- YTD return
- -31.11%
- 1-year return
- -40.93%
- Volume
- 298.14K
- Avg volume
- 180.30K
- Open
- 8.67
- Previous close
- 8.40
- Day's range
- 8.67 – 9.39
- 52-week range
- 7.89 – 15.86
- Beta
- 0.88
- Analysts
- Strong Buy
- Price target
- 25.43 (+174.0%)
- Earnings date
- Feb 11, 2025
2Y -1.02 (-9.88%)
Key statistics
- Enterprise value
- 62.15M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.68M
- Total cash
- 50.87M
- Total debt
- 284.00K
- Return on equity
- -91.68%
- Short % of float
- 0.72%
- 50-day average
- 10.82
- 200-day average
- 8.69
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 25.43 +174.0% upside
Now 9.28
- Target (low)
- 17.00
- Target (mean)
- 25.43
- Target (high)
- 35.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate -0.39.
Financials — quick view
BNTC Revenue — quarterly 0
BNTC Net income — quarterly -12.81M
BNTC EPS — quarterly -0.26
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | -1.00 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | -0.61 | -0.48 | +0.13 | +21.31% |
| Sep 26, 2024 | Jun 1, 2024 | -0.58 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -1.64 | — | — |
| Feb 13, 2024 | Dec 1, 2023 | 0.00 | -2.64 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -2.76 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Baird | init | — | Outperform |
| Dec 3, 2024 | Guggenheim | reit | Buy | Buy |
| Jul 22, 2024 | Leerink Partners | init | — | Outperform |
| Jun 13, 2024 | Piper Sandler | init | — | Overweight |
| Apr 22, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Feb 15, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- benitec.com
News
Benitec Biopharma Announces Its Interim Data From BB-301 Phase 1b/2a Trial Shows Continued Durable Enhancements In Participants Treated With Low Dose Of BB-301; 100% Response Rate Seen Across All Patients Treated 
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 
This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday 
Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14 
Benitec Biopharma (NASDAQ:BNTC) Share Price Breaks Below 50-Day Moving Average – Here’s What Happened 
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study 
Benitec Biopharma (NASDAQ:BNTC) Stock Crosses Below 50 Day Moving Average – Here’s Why 
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC) 
Benitec Biopharma (BNTC) Projected to Release Quarterly Earnings on Monday 
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
Your note
Sign in to keep a note on BNTC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOSTON MEGAN JOAN | Officer and Director | Purchase | Aug 10, 2023 | 25,927 |
| BUCHI J. KEVIN | Director | Purchase | Aug 10, 2023 | 52,097 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 2, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 38.03% | 8,829,053 | 102.24M | Sep 29, 2024 |
| Janus Henderson Group PLC | 3.78% | 876,523 | 10.15M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 3.62% | 841,395 | 9.74M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 3.61% | 838,095 | 9.71M | Sep 29, 2024 |
| Franklin Resources, Inc. | 3.43% | 796,644 | 9.23M | Sep 29, 2024 |
| AWM Investment Company, Inc. | 2.69% | 625,000 | 7.24M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 2.47% | 573,221 | 6.64M | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 0.90% | 207,793 | 2.41M | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Health Care ETF | 0.50% | 116,535 | 1.35M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.21% | 47,680 | 552.13K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 15,669 | 181.45K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 11,397 | 131.98K | Oct 30, 2024 |